PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial

PRF Technologies Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OcuRing™-K. This clearance allows the company to initiate a Phase II clinical trial for OcuRing™-K, a drop-less, sustained-release therapy designed to treat pain and inflammation following cataract surgery. The OcuRing™-K is a bio-erodible intraocular ring that delivers ketorolac through a single intraoperative application, aiming to improve patient compliance and post-operative care. The Phase II trial, expected to begin enrollment in the second half of 2026, will evaluate endpoints related to pain reduction, inflammation control, and safety. PRF Technologies believes this development advances its ophthalmic drug-delivery strategy and addresses a significant unmet need in the market.